TW201705969A - 新穎馬利乳酸桿菌aps1及其用途 - Google Patents
新穎馬利乳酸桿菌aps1及其用途 Download PDFInfo
- Publication number
- TW201705969A TW201705969A TW104125376A TW104125376A TW201705969A TW 201705969 A TW201705969 A TW 201705969A TW 104125376 A TW104125376 A TW 104125376A TW 104125376 A TW104125376 A TW 104125376A TW 201705969 A TW201705969 A TW 201705969A
- Authority
- TW
- Taiwan
- Prior art keywords
- lactobacillus
- composition
- group
- aps1
- diabetes
- Prior art date
Links
- 241000186851 Lactobacillus mali Species 0.000 title claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 29
- 208000008589 Obesity Diseases 0.000 claims abstract description 21
- 235000020824 obesity Nutrition 0.000 claims abstract description 21
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 241000186660 Lactobacillus Species 0.000 claims description 50
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 49
- 239000008103 glucose Substances 0.000 claims description 48
- 229940039696 lactobacillus Drugs 0.000 claims description 48
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 29
- 206010022489 Insulin Resistance Diseases 0.000 claims description 21
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 16
- 208000030159 metabolic disease Diseases 0.000 claims description 16
- 210000000577 adipose tissue Anatomy 0.000 claims description 13
- 230000037396 body weight Effects 0.000 claims description 12
- 201000001421 hyperglycemia Diseases 0.000 claims description 12
- 230000004584 weight gain Effects 0.000 claims description 10
- 235000019786 weight gain Nutrition 0.000 claims description 10
- 208000016097 disease of metabolism Diseases 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- 238000011161 development Methods 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- 238000011160 research Methods 0.000 claims description 8
- 208000002249 Diabetes Complications Diseases 0.000 claims description 7
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 206010012655 Diabetic complications Diseases 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 235000013322 soy milk Nutrition 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000006186 oral dosage form Substances 0.000 claims description 5
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 4
- 239000007937 lozenge Substances 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 241000131482 Bifidobacterium sp. Species 0.000 claims description 3
- 201000001431 Hyperuricemia Diseases 0.000 claims description 3
- 241000186610 Lactobacillus sp. Species 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 235000015218 chewing gum Nutrition 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 3
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 claims description 2
- 229920002261 Corn starch Polymers 0.000 claims description 2
- 241001495410 Enterococcus sp. Species 0.000 claims description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 2
- 240000003183 Manihot esculenta Species 0.000 claims description 2
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 241000194017 Streptococcus Species 0.000 claims description 2
- 241000194022 Streptococcus sp. Species 0.000 claims description 2
- 239000005862 Whey Substances 0.000 claims description 2
- 102000007544 Whey Proteins Human genes 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 239000008120 corn starch Substances 0.000 claims description 2
- 235000015140 cultured milk Nutrition 0.000 claims description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 2
- 241000411851 herbal medicine Species 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 235000011496 sports drink Nutrition 0.000 claims description 2
- 235000015192 vegetable juice Nutrition 0.000 claims description 2
- 229940100445 wheat starch Drugs 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 230000000580 secretagogue effect Effects 0.000 claims 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims 1
- 235000011850 desserts Nutrition 0.000 claims 1
- 201000005577 familial hyperlipidemia Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 7
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract description 6
- 235000009200 high fat diet Nutrition 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 38
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
- 235000005911 diet Nutrition 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- 230000037213 diet Effects 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 235000021050 feed intake Nutrition 0.000 description 9
- 239000006041 probiotic Substances 0.000 description 9
- 235000018291 probiotics Nutrition 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- 235000021590 normal diet Nutrition 0.000 description 8
- 238000013116 obese mouse model Methods 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 108020004465 16S ribosomal RNA Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000000529 probiotic effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 244000199866 Lactobacillus casei Species 0.000 description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 229940017800 lactobacillus casei Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000007410 oral glucose tolerance test Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000020931 dietary conditions Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 235000015141 kefir Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000010603 microCT Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 238000001057 Duncan's new multiple range test Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 239000011121 hardwood Substances 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 102000027411 intracellular receptors Human genes 0.000 description 1
- 108091008582 intracellular receptors Proteins 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000007269 microbial metabolism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000004053 pancreatic β cell dysfunction Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000031337 regulation of inflammatory response Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000028201 sequestering of triglyceride Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 230000009751 type B pancreatic cell apoptotic process Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Abstract
本發明係關於一種新穎馬利乳酸桿菌APS1。此菌株可用於製備預防或治療代謝症候群之組成物。本發明亦關於一種馬利乳酸桿菌用於製備預防或治療肥胖、糖尿病或其併發症之組成物之用途。
Description
本發明係關於一種馬利乳酸桿菌(Lactobacillus mali),特別是關於一種用於製備預防或治療肥胖、糖尿病或其併發症等代謝症候群之組成物之馬利乳酸桿菌APS1。
由於生活習慣的改變,肥胖(obesity)已被列為最新的流行病(Bleich et al.,2008),其發病率在全球不斷的攀升當中,根據世界衛生組織的估計,至2025年肥胖人口數將達到六百萬人(Serino et al.,2009)。肥胖的定義為體內累積過多的脂肪含量而造成脂肪細胞的膨脹擴大,主要是由於攝取過多營養分過高的飲食而造成體重增加,並且使代謝產生異常。這些肥胖人口為隱藏複雜代謝綜合症狀之高危險群,其中混雜的病理情況包括胰島素阻抗(insulin resistance,IR)、葡萄糖耐受性改變、脂肪肝、血脂異常,並與多種代謝疾病相關,如第二型糖尿病及心血管疾病。
根據衛福部統計,糖尿病為我國十大死因第四位,其中95%糖尿病患者,皆屬於非遺傳性之第二型糖尿病(Ministry of Health and Welfare,Executive Yuan,2012)。除
對於葡萄糖的代謝能力降低而造成過高的血糖濃度之外,嚴重糖尿病患者將產生視網膜病變、腎臟病變及神經與循環系統等併發症而使死亡率大幅提升。然而,目前針對第二型糖尿病並無有效的藥物治療,其治療方法仍以飲食控制與提高運動量做為建議。
另一方面,有愈來愈多的證據支持炎症(inflammation)在代謝性疾病的發展上扮演關鍵角色(Hotamisligil,2006)。在長期超負荷營養狀態下,特別是在內臟脂肪所產生之慢性的、低度的發炎,巨噬細胞浸潤產生大量的促炎細胞激素與趨化素(chemokines),如瘦體素(leptin)、腫瘤壞死因子-α(tumor necrosis factor-α,TNF-α)、巨噬細胞趨化蛋白-1(macrophage chemoattractant protein-1,MCP-1)及介白素-6(interleukin-6,IL-6),這些產物與肥胖個體的脂肪組織中固有的脂肪細胞改變了脂肪組織功能,損害三酸甘油酯的儲存與游離脂肪酸的循環,使肥胖個體產生病理失調,因而發生胰島素阻抗(Fantuzzi,2005;Sesti,2006)。
近年來,許多研究發現腸道微生物菌相分布與肥胖有顯著相關性(Backhed et al.,2007)。健康的個體與肥胖/第二型糖尿病的患者間腸道菌相組成有很大的差異,可能是造成這些代謝疾病的重要因子(Cani et al.,2009;Caesar et al.,2010;Musso et al.,2010;Delznne and Cani,2011;Frazier et al.,2011;Greiner and Bäckhd,2011;Cani et al.,2012;Tremaroli and Bäckhd,2012)。
腸道微生物代謝的營養主要來自宿主飲食,兩者之間
的交互作用可產生能量,並刺激免疫系統及內分泌(Delznne and Cani,2011;Tremaroli and Bäckhd,2012)。腸道菌相中,格蘭氏陽性/陰性菌比例與宿主能量代謝、血中內毒素含量與調節發炎反應之調控息息相關,雖然機制尚未明瞭,但同時與宿主基因表現及生活型態三者交互影響下,產生如肥胖與糖尿病等飲食失調之代謝症狀(Cani et al.,2007;Lye et al.,2009)。
因此,益生菌(probiotics)應用於代謝症狀改善上之研究逐漸嶄露頭角。常見的益生菌種皆屬格蘭氏陽性菌,如乳酸桿菌(Lactobacillus sp.)及雙叉乳桿菌(Bifidobacterium sp.),其可增進宿主健康,包括抑制病原菌生長、促進腸道菌相平衡、降低乳糖不耐與食物過敏症狀(McFarland et al.,2000;Andersson et al.,2001;Salmincn et al.,2001)。
回顧過去文獻,Matsuzaki et al.(1997)使用乾酪乳酸桿菌(Lactobacillus casei)之活菌與死菌口服給予胰島素阻抗模式KK-Ay小鼠,發現在小鼠八至十周齡時可顯著降低其血糖含量,且在相同飼糧下體重也有下降趨勢。關於以高脂飲食(high-fat-diet,HF)誘導小鼠產生糖尿病症狀之試驗,Cani et al.(2007)利用雙叉乳桿菌屬混合菌株添加於高脂飲食餵飼小鼠,發現比起控制組可顯著改善糖耐受性,以及降低內臟脂肪組織的重量。Yadav et al.(2007)利用含有嗜酸乳桿菌(Lactobacillus acidophilus)及乾酪乳酸桿菌之活菌之印度傳統發酵製品,餵飼經高糖飲食誘導產生高血糖之小鼠,比起控制組顯著降低糖耐受性、血糖濃度、血
總膽固醇、三酸甘油酯、低密度脂蛋白、極低密度脂蛋白及揮發性脂肪酸之含量,因而推測含有嗜酸乳桿菌及乾酪乳酸桿菌之活菌之發酵製品可減緩肥胖所誘導的第二型糖尿病之發展。
由此可見,益生菌之免疫調節能力、降低血膽固醇、抗高血壓、改善飲食失調及糖尿病的能力已進一步應用在代謝疾病的預防與臨床治療(Lye et al.,2009)。
本發明發現馬利乳酸桿菌(Lactobacillus mali,本文中有時簡稱為Lb.mali APS1)具有改善代謝症候群的能力,可用以預防或治療肥胖、糖尿病等代謝疾病。
本發明提供一種經單離的馬利乳酸桿菌APS1,其係於2015年3月17日寄存於食品工業發展研究所之生物資源保存及研究中心,寄存編號為BCRC 910674。
於本發明之一態樣中,亦提供一種組成物,其包括經單離的馬利乳酸桿菌APS1及其載劑,該經單離的馬利乳酸桿菌APS1係寄存於食品工業發展研究所之生物資源保存及研究中心,寄存編號為BCRC 910674。
根據本發明之一具體實施例,該組成物係醫藥組成物、食品補充劑或食品。根據本發明之一具體實施例,該組成物係口服劑型。較佳地,該口服劑型係選自下列所組成群組之其中一者:溶液、懸浮液、乳劑、粉末、錠劑、九劑、糖漿、口含錠、片劑、口嚼膠、膠囊及其組合。
根據本發明之一具體實施例,該組成物進一步包括選
自由下列所組成群組之菌株:乳酸桿菌屬物種(Lactobacillus sp.)、雙叉乳桿菌屬物種(Bifidobacterium sp.)、鏈球菌屬物種(Streptococcus sp.)、酵母菌、腸球菌屬物種(Enterococcus sp.)、桿菌屬物種(Bacillus sp.)及其組合。
根據本發明之一具體實施例,該組成物中包括之載劑係選自下列所組成群組可食性材料之其中一者:水、牛乳、乳清、發酵乳、優格、乳粉、乳酪、果汁、蔬菜汁、豆奶、豆漿、發酵豆奶、運動飲料、甜點、糖果、中藥材、動物飼料、玉米澱粉、小麥澱粉、木薯澱粉、麥芽胡精(maltodextrin)及其組合。
於本發明之又一態樣中,係提供一種馬利乳酸桿菌用於製備預防或治療代謝性疾病之組成物的用途。根據本發明之一具體實施例,該馬利乳酸桿菌為經單離的馬利乳酸桿菌APS1,其係寄存於食品工業發展研究所之生物資源保存及研究中心,寄存編號為BCRC 910674。
根據一具體實施例,該代謝性疾病係選自由下列所組成群組之其中一者:肥胖、糖尿病、糖尿病併發症、高血脂症、高血糖症、脂肪肝、高尿酸血症、高血壓及其組合。
於本發明之一較佳具體實施例中,該代謝性疾病係肥胖。根據本發明之一具體實施例,以馬利乳酸桿菌所製備之該組成物係用以減少體重及/或抑制體重增加。根據一具體實施例,該肥胖係由於體脂肪生成或內臟脂肪含量增加導致。
於本發明之另一較佳具體實施例中,該代謝性疾病係
糖尿病或糖尿病併發症。根據本發明之一具體實施例,該糖尿病係由選自下列所組成之群組的因素造成:胰島素阻抗、葡萄糖耐受性異常、高血糖、高三酸甘油脂、高總膽固醇、高LDL/HDL比值、低GLP-1濃度及其組合。根據一具體實施例,該糖尿病為第二型糖尿病,而該糖尿病併發症係選自由下列所組成群組之其中一者:視網膜病變、腎臟病變、神經系統病變、循環系統病變及其組合。
根據本發明之一具體實施例,以馬利乳酸桿菌所製備之該組成物係用以降低一或多個選自由下列所組成之群組者之量:葡萄糖、總膽固醇及其組合。根據本發明之另一具體實施例,該組成物係用以增加GLP-1之量。
第1圖顯示馬利乳酸桿菌APS1與馬利乳酸桿菌KCTC 3596之基因體DNA序列差異,上方為馬利乳酸桿菌APS1之基因體DNA序列;下方為馬利乳酸桿菌KCTC 3596之基因體DNA序列。
第2A(a)至2E圖顯示Lb.mali APS1對於高脂飼糧引起的體重增加之影響。第2A(a)及2A(b)圖顯示每周小鼠之體重變化及經8周處理後之小鼠體重增加情形;第2B(a)及2B(b)圖顯示每周小鼠之採食量變化及8周內之總採食量;第2C圖為具代表性之微米級電腦斷層掃描圖,顯示經8周處理後之小鼠體脂肪累積情形;第2D圖顯示經電腦斷層測量後小鼠全身之體脂肪比例及第2E圖顯示肝臟重量。CT:控制組,餵食正常飼糧(含10%脂肪);HF:高
脂飼糧組,餵食高脂飼糧(含60%脂肪);M1:餵食高脂飼糧及108CFU之Lb.kefiranofaciens M1;APS1:餵食高脂飼糧及108CFU之Lb.mali APS1。數據係以平均標準差表示。*P<0.01,與控制組比較;#P<0.05,與高脂飼糧組比較。
第3A至3H圖顯示Lb.mali APS1對於高脂飼糧餵飼之小鼠其葡萄糖耐受性、代謝荷爾蒙及胰島素阻抗之影響。第3A及3B圖分別顯示小鼠於第4周時之血糖濃度變化及血液葡萄糖曲線下面積(AUG葡萄糖);第3C及3D圖分別顯示小鼠於第8周時之血糖濃度變化及血液葡萄糖曲線下面積(AUG葡萄糖);第3E至3G圖分別顯示血液中葡萄糖、GLP-1及胰島素之濃度;第3H圖顯示穩態模式胰島素阻抗指數(HOMA-IR)。CT:控制組,餵食正常飼糧(含10%脂肪);HF:高脂飼糧組,餵食高脂飼糧(含60%脂肪);M1:餵食高脂飼糧及108CFU之Lb.kefiranofaciens M1;APS1:餵食高脂飼糧及108CFU之Lb.mali APS1。數據係以平均標準差表示。*P<0.05,與控制組比較。
第4A至4D圖顯示餵飼小鼠高脂飼糧八周後,開始恢復正常飼糧,並餵飼Lb.mali APS1四周,對於相同飲食條件下的肥胖個體減重之影響。第4A圖顯示每周小鼠之平均採食量;第4B圖顯示經1個月處理後之小鼠體重減少之情形;第4C及4D圖分別顯示小鼠之體脂肪重及肝臟重量。正常小鼠:負控制組,餵食正常飼糧(含10%脂肪);肥胖小鼠:正控制組,餵食高脂飼糧8周後餵食正常飼糧;
肥胖小鼠+APS1:益生菌處理組,餵飼高脂飼糧8周後餵食正常飼糧及108之Lb.mali APS1菌株。
以下係提供利用本發明之實施例以舉例說明本發明之優點與技術特徵,然本實施例並非用以限定本發明,任何熟悉此技藝者,在不脫離本發明之精神和範圍內,當可作各種之更動與潤飾,因此,本發明之保護範圍,當視後附之申請專利範圍所界定者為準。
本發明係關於馬利乳酸桿菌之用途,其係用於製備治療或預防肥胖、糖尿病、或其併發症等代謝症候群之組成物。
如本文所使用者之「胰島素阻抗」係指為目標組織對胰島素的敏感性降低的病理情況。胰島素阻抗會導致葡萄糖運輸降低及肝醣生成減少。在由於高負荷量營養濃度的攝取而營造出體內慢性高血糖的環境下,可直接誘導胰島素阻抗的產生,其機制為減少細胞內受體的數量及降低胰島素的親和力,因此改變了細胞膜因子的特性,使胰島素受體不易進行磷酸化,進而影響胰島素受體對於血糖平衡的訊息傳遞,而這種缺陷反映在目標組織對葡萄糖代謝異常上(Bloomgarden,1998)。與肥胖相關的胰島素阻抗是引導第二型糖尿病發展的主要核心,肥胖者因目標組織對葡萄糖的代謝降低,使得血糖無法回復正常狀態,而長期血糖過高使胰臟β細胞凋亡而產生功能障礙,體內游離脂肪酸值的升高抑制了肌肉中葡萄糖的氧化與吸收利用,使個體
降血糖機制失調而產生胰島素阻抗。此外,胰島素阻抗亦可能誘發高血壓、血脂異常、動脈粥樣硬化與心血管疾病的發生,故胰島素阻抗同時也是許多臨床疾病的共同特徵,包括葡萄糖耐受性異常、肥胖、血脂異常與高血壓累聚所謂之代謝症候群(Sesti,2006)。
如本文所使用之「類升糖素胜肽-1(GLP-1)」係指一種增泌素(Incretin)類荷爾蒙,由腸胃道的L細胞經食物刺激後所分泌,具有促使胰島素在胰臟β細胞中合成及表現的促胰島素功能,可促進血糖代謝維持平衡。
如本文所使用之「代謝性疾病」包括肥胖、糖尿病、高血脂症(如高血三酸甘油酯及高血膽固醇)、高血糖症、脂肪肝、心血管疾病、高尿酸血症、胰島素阻抗高血壓等。
如本文所使用之「口服糖耐受測試」係指世界衛生組織建議之糖尿病診斷標準,可偵測出第二型糖尿病的潛伏期階段(Shulman,2000),血糖正常或偏高者接受口服葡萄糖耐受測試後,若有胰島素不正常升高之現象,可視為胰島素敏感降低及胰臟β細胞功能不良的證據。
如本文所使用之「治療」不一定意謂治癒疾病或病症,亦可將與病症或疾病相關之症狀之減輕描述為治療。此外,亦可將使病症或疾病之進展減緩描述為治療。
如本文所使用之「有效量」表示為達成特定用途所需要之物質之量。因此,有效量可視特定用途而變化。用於本發明之馬利乳酸桿菌之有效量可由多種相關因子決定,包括所欲治療的疾病類型、投予途徑、患者年齡、性別、
體重及罹病嚴重程度。
此外,包含用於本發明之馬利乳酸桿菌之組成物可進一步包括醫藥上可接受之載劑。以口服劑型而言,醫藥上可接受之載劑可包括黏結劑、潤滑劑、崩解劑、賦形劑、助溶劑、分散劑、安定劑、懸浮劑、著色劑及香料。此等醫藥上可接受之載劑之實例包括乳糖、葡萄糖、蔗糖、山梨糖醇、甘露糖醇、木糖醇、赤蘚醇、麥芽糖醇、澱粉、亞拉伯膠、藻酸鹽、明膠、磷酸鈣、矽酸鈣、纖維素、甲基纖維素、微晶纖維素、聚乙烯基吡咯啶酮、水、甲基羥基苯甲酸酯、丙基羥基苯甲酸酯、滑石、硬脂酸鎂及礦物油。
以下係藉由特定之具體實施例進一步說明本發明之特點之功效,但非用於限制本發明之範疇。
馬利乳酸桿菌(Lactobacillus mali,Lb.mali)APS1菌株係由國立臺灣大學動物產品實驗室自發酵食品中分離出。菌株培養過程為:使用黑糖粉以5%(w/v)的比例配製成黑糖液,與全脂牛乳和全脂羊乳均經過121℃、15分鐘之滅菌程序後,接種5%(w/w)的糖液克弗爾粒(kefir grain),於20℃恆溫培養箱進行發酵。隨後,取10g活化完成之糖液克弗爾粒,以無菌水清洗後置於滅菌鐵胃袋中,加入90g已滅菌之0.85%氯化鈉溶液,利用鐵胃均質機以中速
(normal speed)均質2分鐘,取1mL均質液進行系列稀釋與培養。
微生物單一菌落之分離步驟為從上述所得之培養基中,挑選菌落數介於30~100之培養基,挑起所有的單一菌落置於適合之培養液活化後,分裝於1.5mL微量離心管中,作為後續菌種鑑定之用。
以普遍性引子8f及1512r增幅乳酸桿菌之16S rDNA全長基因片段,將所得的產物進行定序分析,使用8f、536f及1512r作為全長三段式定序之引子組(如表1所示),經分離之馬利乳酸桿菌16s rDNA定序結果為SEQ ID NO.1。將定序所得之結果使用Basic Local Alignment Search Tool(BLAST,http://blast.ncbi.nlm.nih.gov/Blast.cgi)功能於Genbank比對菌株之身分。比對結果如表2所示。
進一步比對所分離之馬利乳酸桿菌APS1及馬利乳酸桿菌LA214之序列,發現馬利乳酸桿菌APS1之16s rDNA全長為1498個核苷酸,馬利乳酸桿菌LA214則僅有1429個核苷酸(對應至馬利乳酸桿菌APS1之16s rDNA中第38至1466個核苷酸之片段)。因此確認本發明所分離之馬利乳酸桿菌APS1為一種新穎的馬利乳酸桿菌。
經過鑑定確認其所屬菌種後,馬利乳酸桿菌APS1於2015年3月17日寄存於食品工業發展研究所之生物資源保存及研究中心,並由寄存單位給予寄存編號為BCRC 910674。此生物材料已經存活試驗測試並通過該試驗。
馬利乳酸桿菌APS1之基因體DNA係利用PrestoTM Mini gDNA Bacteria Kit(Geneaid Biotech.Ltd.)並依據其使用說明來萃取。所萃取之DNA樣品的光密度(optical density,OD)260/280值介於1.8至2.0之間,且其藉由Qubit versus NanoDrop所測得之數量比(quantity ratio)大於0.7,顯示該DNA樣品可用於後續的染色體定序流程。
接著,將10μg之總DNA以Misonix 3000超音波振盪器振盪成400至500bp的大小(DNA之尺寸係藉由bioanalyzer DNA 1000 chip(Agilent Technologies)測定)。將1μg經振盪之DNA進行末端修復(end-repair)、A-拖尾(A-tail)及轉接器接合(adaptor-ligate),然後進行Illumina's TruSeq DNA製備程序,以建立序列資料庫。
將所得之DNA序列進行過濾以獲得適當的讀取物(reads)。根據該等讀取物之質量分數,使用Trimmomatic對該等讀取物進行修整或移除,再藉由Velvet將經清理及修整之核讀取物(nuclear reads)重新(de novo)組裝,並以透過自我訓練(self-training)來操作馬利乳酸桿菌之GeneMark模式創造MAKER 2.00版之基因體註解(Genome annotation)。接著,使用BLASTP將所得之預測結果與NCBI之非冗餘(non-redundant,nr)數據庫比對。
第1圖顯示馬利乳酸桿菌APS1與已知菌株(馬利乳酸桿菌KCTC 3596=DSM 20444)的比對結果,顯示兩者之差異與相同之處。於第1圖中,上方為馬利乳酸桿菌APS1
之基因體DNA序列;下方為馬利乳酸桿菌KCTC 3596之基因體DNA序列。比對結果顯示,馬利乳酸桿菌APS1與馬利乳酸桿菌KCTC 3596之基因體DNA序列之相似度為54.54%。
以API鑑定經分離之馬利乳酸桿菌APS1對各種不同碳水化合物基質的之碳源利用情形,分析結果如表3所示。
取1mL馬利乳酸桿菌APS1菌液進行系列稀釋,使用Lactobacilli deMan,Rogosa and Sharp(MRS)培養基(Lactobacilli MRS agar,Merck)進行培養,經37℃培養48小時後,選取菌落數量介於30-300顆之間的組別,並挑起培養基表面上之單一菌落置於MRS培養液中活化,分裝於1.5mL離心管,作為後續試驗之用。Lb.mali APS1菌株
冷凍小管使用MRS培養液(Difco Laboratories,Detroit,MI),於37℃活化後,將對數生長期之菌株以離心方式回收菌體,並重新懸浮於磷酸鹽緩衝液(phosphate buffer solution,PBS)(Hyclone,South Logan,UT)並調整菌數為108CFU/mL。
將40隻七周齡C57BL/6jNarl品系雌性小鼠(BioLASCO Taiwan Co.,Ltd,Taipei,Taiwan)飼養於鋪有墊料(Beta Chip®heat treated hardwood laboratory bedding,Northeastern Products Corp.,Warrensburg,NY,USA)之飼育籠內,每隻獨立飼養,給予充足的標準飼糧及飲用水;動物房設有自動控制光照循環週期,12小時光照、12小時黑暗,並維持溫度在22~25℃、溼度40%~60%,且開啟通風扇維持空氣流通。
小鼠於馴養一周後以高脂飼糧進行肥胖誘導,主要參考Neyrink et al.(2012)進行。將小鼠分成4組(每組10隻):控制組(CT)餵食控制組精製飼糧(D12450B;research diets,Inc.,New Brunswick,NJ,USA),內含10%脂肪;高脂飼糧組(HF)餵食高脂飼糧,並每日口服給予PBS溶液;另外兩組為益生菌處理組:益生菌對照組(M1組)及馬利乳酸桿菌組(APS1組),分別餵食高脂飼糧,並每日口服給予馬乳酒乳酸桿菌(Lb.kefiranofaciens)M1 108CFU及Lb.mali APS1 108CFU。持續進行八周,每周針對體重及採食量進行紀錄
觀察。
高脂飼糧成分包含60%脂肪、20%碳水化合物及20%蛋白質[kcal/100g](D12492;Research Diets,Inc.,New Brunswick,NJ,USA)。高脂飲食飼糧在採食量上低於正常配方,此飼糧配方可在短時間誘導小鼠體重上升,可有效縮短代謝試驗之動物飼養期程。經過精製之成分,可減少因高脂成分所導致其他營養分產生稀釋效果。
如第2A(a)及2A(b)圖所示,經8周餵食高脂飼糧之小鼠,其體重以每周增加10至15%持續上升,而餵食Lb.mali APS1之處理組可顯著減緩體重增加的現象產生。
在顯著的體重差異變化下,此試驗同時針對採食量進行監控。每周測定小鼠採食量,如第2B(a)及2B(b)圖所示,發現餵食高脂飼糧之三組處理組(HF組、M1組及APS1組)之間,小鼠採食量無顯著差異,因此可排除小鼠體重的差異來自於採食量的多寡。
為了解造成體重差異是否源於體組成之變化,將以實施例5中所述之方式餵食8周後之小鼠,利用Minispec LF50 TD-NMR(Time-Domain Nuclear Magnetic Resonance analyzer,Bruker Madison,USA)核磁共振技術進行體組成分析,包括
體脂肪、體瘦肉及體液比例。另以SkyScan1176 Micro-CT System(Micro Photonics Inc.,Allentown,PA,USA)進行微米級電腦斷層掃描(micro-computed tomography)活體影像顯影分析小鼠體脂肪累積部位與情形。
如第2C及2D圖所示,APS1組顯著降低小鼠體內脂肪堆積情形,體脂肪佔全身比例的19.4±3.24%,顯著低於HF處理組的27.15±1.7%。而第2E圖顯示肝臟重量,發現Lb.mali APS1可避免小鼠在高脂飼糧供應下,肝臟因脂肪堆積而產生顯著的重量增加,與餵飼正常配方飼糧之組別無顯著差異。
由於胰島素阻抗患者通常具有高血糖、高血清胰島素、高血脂症等症狀。因此,血液中葡萄糖、血清胰島素、三酸甘油酯、膽固醇與游離脂肪酸之含量測定,在降低胰島素阻抗之菌株篩選上即成重要指標。
此試驗使用國家實驗動物中心之血液生化檢測儀器(FDC 3500,Fujifilm,Tokyo,Japan),針對以實施例5中所述之方式餵食8周後之小鼠,進行空腹血糖(GLU)、三酸甘油脂(TG)、總膽固醇(T-CHOL)、高密度脂蛋白膽固醇(HDL-cholesterol)及低密度脂蛋白膽固醇(LDL-cholesterol)、血液中之尿素氮(blood urea nitrogen,BUN)之檢測分析。
試驗結果如表4所示,餵飼Lb.mali APS1可顯著降
低小鼠體內GLU及T-CHOL之濃度。
CT組:餵食正常飼糧(含10%脂肪);HF組:餵食高脂飼糧(含60%脂肪);M1組:餵食高脂飼糧及108CFU之馬乳酒乳酸桿菌M1;APS1組:餵食高脂飼糧及108CFU之Lb.mali APS1。數據係以平均標準差表示。*P<0.01,與CT組比較;#P<0.05,與HF組比較。
為了解小鼠體內血糖變化情形,以實施例5中所述之方式建立肥胖小鼠動物模式,並於第4周及第8周時進行小鼠口服糖耐受測試。測試前先將小鼠禁食6小時後,以
口服方式給予葡萄糖(3g/kg體重,66%葡萄糖溶液),隨後,於葡萄糖給予前30分鐘、葡萄糖給予後當下及葡萄糖給予後第15、30、60、90及120分鐘時進行小鼠尾靜脈採血,並以血糖機(Roche Diagnostics,Indiana,USA)進行血糖濃度測定,計算血液葡萄糖曲線下面積(AUG葡萄糖)。
第3A及3B圖分別顯示小鼠於第4周時之血糖濃度變化及血液葡萄糖曲線下面積(AUG葡萄糖);第3C及3D圖分別顯示小鼠於第8周時之血糖濃度變化及血液葡萄糖曲線下面積(AUG葡萄糖);第3E圖則顯示小鼠於第8周時之血液中葡萄糖之濃度。
如第3A至3E圖所示,高脂飼糧造成小鼠對於葡萄糖之耐受性降低,說明其體內胰島素作用時間增長,相較於控制組,顯著地產生體內高血糖症狀。而Lb.mali APS1則可顯著降低血糖及AUG葡萄糖,增加葡萄糖的耐受性,改善高脂飼糧所誘導的高血糖症狀,與餵食正常飼糧的控制組無顯著差異。
本實施例係針對小鼠血液中之代謝荷爾蒙進行分析。以實施例5中所述之方式建立肥胖小鼠動物模式後,使用MILLIPLEX® ELISA分析套組(EMD Millipore Corporation,Billerica,MA,U.S.A.)進行血中胰島素及GLP-1測定。所有代謝荷爾蒙測定前皆加入蛋白酶抑制劑(Dipeptidyl peptidase-4 inhibitor),以減少待測物之降解破
壞。
結果如第3F及3G圖所示,Lb.mali APS1可誘發較高濃度的GLP-1生成(40.08±8.83pg/mL);胰島素濃度則是以HF組及M1組較高,分別為2823±95及3146±793pg/mL。此結果與體重上升的表現類似,認為是肥胖小鼠體內血糖長期偏高,使得胰島素敏感性降低,且因胰島素製造、儲存及分泌異常而產生代償性分泌增加,使體內產生高血糖與高胰島素的狀態,此為標準二型糖尿病中期的過度階段。
將相關血糖調節因子之結果以穩態模式胰島素阻抗指數(Homeostatic Model Assessment-IR,HOMA-IR)進行換算,結果如第3H圖所示,說明餵食Lb.mali APS1之組別顯著改善高脂飼糧造成小鼠胰島素阻抗的現象。
為模擬減重者所進行的體重控制,本實施例進行肥胖小鼠減重測試。本實施例選用30隻六周齡C57BL/6jNarl品系雄性小鼠(BioLASCO Taiwan Co.,Ltd,Taipei,Taiwan),並依照實施例5所述之飼養環境飼養。將小鼠分成3組(每組10隻):負控制組餵食以AIN-93為營養基礎之精製飼糧,其餘動物皆餵飼以AIN-93為基礎進行修飾之高脂飼糧,包括正控制組:餵食高脂飼糧8周誘導肥胖後,於第9周開始餵飼負控制組飼糧,並每日口服給予PBS溶液;另外1組益生菌處理組則餵飼高脂飼糧8周誘導肥胖
後,於第9周開始餵飼負控制組飼糧,並每日口服給予108之Lb.mali APS1菌株。更換飼糧及口服處理1個月後,針對小鼠體重、體脂肪及肝臟重量進行比較。
第4A至4D圖顯示各組小鼠體重皆下降,在採食量沒有差異的條件下(見第4A圖),APS1組體重下降幅度較大(見第4B圖),同時顯著降低體脂肪及改善肥胖者脂肪累積於肝臟所增加的重量(見第4C及4D圖)。
所有試驗皆經過三重複測定後,將所得之數據以Microsoft®Office Excel®2010(Microsoft Corp.,Redmond,WA,USA)繪圖,利用SAS套裝軟體(SAS institute,ver.9.1 for Windows,Cary,NC,USA)進行變異數分析(analysis of variance,ANOVA);以鄧肯氏新多變域檢定法(Duncan's new multiple range test)檢測各處理組平均值間之差異顯著性。
綜上所述,在肥胖小鼠模式中,體重變化、體組成變化、口服糖耐受測試分析、血液生化值分析、代謝荷爾蒙測定結果都顯示馬利乳酸桿菌具有卓越的能力可以改善代謝疾病症狀,並且對於減重及減少體脂肪生成呈現出良好之成效,因此馬利乳酸桿菌確實為極具潛力的益生菌,可與其他益生菌種混合,或加入可食性材料,以作為食品、食品補充劑或飼料添加物,並發揮改善代謝症候群的功能。此外,馬利乳酸桿菌也可以和醫藥上可接受之載劑混
合,以製備成溶液、懸浮液、乳劑、粉末、錠劑、丸劑、糖漿、口含錠、片劑、口嚼膠或膠囊之劑型,供一般應用或醫藥使用。
<110> 國立臺灣大學
<120> 新穎馬利乳酸桿菌APS1及其用途
<130> 113388
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 1498
<212> 16S rDNA
<213> 馬利乳酸桿菌
<220>
<221> gene
<222> (1)..(1496)
<400> 1
<210> 2
<211> 20
<212> DNA
<213> 人工序列
<220>
<223> 8f引子
<220>
<221> misc_difference
<222> (1)..(20)
<400> 2
<210> 3
<211> 18
<212> DNA
<213> 人工序列
<220>
<223> 1512r引子
<220>
<221> misc_difference
<222> (1)..(18)
<400> 3
<210> 4
<211> 18
<212> DNA
<213> 人工序列
<220>
<223> 536f引子
<220>
<221> misc_difference
<222> (1)..(18)
<400> 4
本案圖式均為實驗數據圖式,故無指定代表圖。
Claims (20)
- 一種經單離的馬利乳酸桿菌(Lactobacillus mali)APS1,係寄存於食品工業發展研究所之生物資源保存及研究中心,寄存編號為BCRC 910674。
- 一種組成物,係包括如申請專利範圍第1項所述之經單離的馬利乳酸桿菌APS1及其載劑。
- 如申請專利範圍第2項所述之組成物,係醫藥組成物、食品補充劑或食品。
- 如申請專利範圍第2項所述之組成物,係口服劑型。
- 如申請專利範圍第4項所述之組成物,其中,該口服劑型係選自下列所組成群組之其中一者:溶液、懸浮液、乳劑、粉末、錠劑、九劑、糖漿、口含錠、片劑、口嚼膠、膠囊及其組合。
- 如申請專利範圍第2項所述之組成物,進一步包括選自由下列所組成群組之菌株:乳酸桿菌屬物種(Lactobacillus sp.)、雙叉乳桿菌屬物種(Bifidobacterium sp.)、鏈球菌屬物種(Streptococcus sp.)、酵母菌、腸球菌屬物種(Enterococcus sp.)、桿菌屬物種(Bacillus sp.)及其組合。
- 如申請專利範圍第2項所述之組成物,其中,該載劑係選自下列所組成群組可食性材料之其中一者:水、牛乳、乳清、發酵乳、優格、乳粉、乳酪、果汁、蔬菜汁、豆奶、豆漿、發酵豆奶、運動飲料、甜點、糖果、中藥材、動物飼料、玉米澱粉、小麥澱粉、木薯 澱粉、麥芽胡精及其組合。
- 一種馬利乳酸桿菌用於製備預防或治療代謝性疾病之組成物的用途。
- 如申請專利範圍第8項所述之用途,其中,該馬利乳酸桿菌為如申請專利範圍第1項所述之經單離的馬利乳酸桿菌APS1。
- 如申請專利範圍第8項所述之用途,其中,該代謝性疾病係選自由下列所組成群組之其中一者:肥胖、糖尿病、糖尿病併發症、高血脂症、高血糖症、脂肪肝、高尿酸血症、高血壓及其組合。
- 如申請專利範圍第10項所述之用途,其中,該代謝性疾病係肥胖。
- 如申請專利範圍第11項所述之用途,其中,該組成物係用以減少體重及/或抑制體重增加。
- 如申請專利範圍第11項所述之用途,其中,該肥胖係由於體脂肪生成或內臟脂肪含量增加導致。
- 如申請專利範圍第10項所述之用途,其中,該代謝性疾病係糖尿病或糖尿病併發症。
- 如申請專利範圍第14項所述之用途,其中,該糖尿病係由選自下列所組成之群組的因素造成:胰島素阻抗、葡萄糖耐受性異常、高血糖、高三酸甘油脂、高總膽固醇、高LDL/HDL比值、低GLP-1濃度及其組合。
- 如申請專利範圍第14項所述之用途,其中,該糖尿病為第二型糖尿病。
- 如申請專利範圍第14項所述之用途,其中,該糖尿病併發症係選自由下列所組成群組之其中一者:視網膜病變、腎臟病變、神經系統病變、循環系統病變及其組合。
- 如申請專利範圍第14項所述之用途,其中,該組成物係用以降低一或多個選自由下列所組成之群組者之量:葡萄糖、總膽固醇及其組合。
- 如申請專利範圍第14項所述之用途,其中,該組成物係用以增加增泌素類荷爾蒙之量。
- 如申請專利範圍第19項所述之用途,其中,該增泌素類荷爾蒙係GLP-1。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW104125376A TWI559925B (en) | 2015-08-05 | 2015-08-05 | Novel lactobacillus mali aps1 and use thereof |
US14/976,152 US9884079B2 (en) | 2015-08-05 | 2015-12-21 | Biologically pure Lactobacillus mali strain and composition thereof for treating metabolic syndrome |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW104125376A TWI559925B (en) | 2015-08-05 | 2015-08-05 | Novel lactobacillus mali aps1 and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
TWI559925B TWI559925B (en) | 2016-12-01 |
TW201705969A true TW201705969A (zh) | 2017-02-16 |
Family
ID=58053236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104125376A TWI559925B (en) | 2015-08-05 | 2015-08-05 | Novel lactobacillus mali aps1 and use thereof |
Country Status (2)
Country | Link |
---|---|
US (1) | US9884079B2 (zh) |
TW (1) | TWI559925B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI699165B (zh) * | 2017-12-15 | 2020-07-21 | 南韓商Cj第一製糖股份有限公司 | 使用馬利乳酸桿菌製造轉葡萄糖基化甜菊醣苷的方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11173455B2 (en) | 2017-04-19 | 2021-11-16 | Lg Chem, Ltd. | Water treatment membrane and method for manufacturing same |
TWI634207B (zh) * | 2017-10-20 | 2018-09-01 | 葡萄王生技股份有限公司 | 一種胚芽乳酸桿菌、組合物、培養方法及降尿酸、改善過敏及/或降血糖的用途 |
CN109492829A (zh) * | 2018-12-13 | 2019-03-19 | 平安医疗健康管理股份有限公司 | 基于人工智能的医保基金支出预测方法及相关装置 |
IT202100011507A1 (it) * | 2021-05-05 | 2022-11-05 | Probionova Sa | Composizioni a base di ceppi di batteri per il trattamento di alterazioni del metabolismo glucidico |
CN113384600B (zh) * | 2021-05-28 | 2024-04-12 | 陕西师范大学 | 一种灭活乳酸菌复合物在制备治疗和/或预防糖尿病产品中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005348698A (ja) * | 2004-06-14 | 2005-12-22 | Yonezawa Biru System Service:Kk | ケフィア粒から分離された微生物とこの微生物あるいはそれを含む微生物群を培養して得られる微生物培養物ならびにそれらを用いた製品 |
EP2205259B1 (en) * | 2007-10-02 | 2014-12-10 | Institut National de la Recherche Scientifique | Mpm (malleable protein matrix) for use in the treatment of arthritis, obesity, insulin resistance, type 2 diabetes, autoimmune disease, hypertension, and hyperlipidemia |
US20130029906A1 (en) * | 2009-12-04 | 2013-01-31 | Eric Simard | Method of regulating ppar, obesity related pathways and their associated metabolic impact |
-
2015
- 2015-08-05 TW TW104125376A patent/TWI559925B/zh active
- 2015-12-21 US US14/976,152 patent/US9884079B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI699165B (zh) * | 2017-12-15 | 2020-07-21 | 南韓商Cj第一製糖股份有限公司 | 使用馬利乳酸桿菌製造轉葡萄糖基化甜菊醣苷的方法 |
Also Published As
Publication number | Publication date |
---|---|
US20170035814A1 (en) | 2017-02-09 |
TWI559925B (en) | 2016-12-01 |
US9884079B2 (en) | 2018-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI572354B (zh) | 抑制發炎之組成物 | |
CN103314099B (zh) | 具有代谢综合症改善效果的乳酸菌 | |
TWI583388B (zh) | 胚芽乳酸桿菌用於製備改善運動表現及降低肌肉疲勞之益生菌組合物之用途 | |
KR102303587B1 (ko) | 건선의 치료 및/또는 예방에서의 프로바이오틱스의 용도 | |
TWI594758B (zh) | 包含雙歧桿菌的組合物、其製備方法及其用途 | |
TW201705969A (zh) | 新穎馬利乳酸桿菌aps1及其用途 | |
TW200944215A (en) | Lactobacillus isolates having anti-inflammatory activities and uses of the same | |
JP5554994B2 (ja) | 乳酸菌含有製剤 | |
US20150328266A1 (en) | Use of Bifidobacterium Animalis for Treating or Preventing Body Weight Gain and Insulin Resistance | |
EP2127660A1 (en) | Agent for reducing visceral fat | |
CN102935092A (zh) | 新颖乳杆菌及其组合物和在制备改善糖尿病及其并发症药物中的应用 | |
JP2019535828A (ja) | ギ酸生成能に優れた菌株を有効成分として含む肥満または肥満によって惹起された代謝症候群の予防または治療用組成物 | |
Qian et al. | Effects of lactobacillus casei YBJ02 on lipid metabolism in hyperlipidemic mice | |
JP2011254743A (ja) | 糖尿病及びその合併症の改善に使われる組成物、改善方法及び乳酸桿菌分離株 | |
KR101545551B1 (ko) | 인슐린 저항성 개선 효능을 갖는 7종의 유산균 복합균주를 유효성분으로 함유하는 조성물 | |
JP5229977B2 (ja) | 血中アディポネクチン濃度増加促進及び/又は減少抑制剤 | |
JP6862464B2 (ja) | フィーカリバクテリウム・ロンガム(Faecalibacterium longum)およびその使用 | |
KR101238836B1 (ko) | 혼합 유산균을 포함하는 비만 또는 비만 관련 질환 치료 또는 예방용 약제학적 조성물 또는 식품 조성물 | |
CN116376740A (zh) | 一株具有降血糖功效的长双歧杆菌及其应用 | |
JP6894242B2 (ja) | 非アルコール性肝障害抑制剤 | |
WO2018174125A1 (ja) | 脂質代謝改善用組成物 | |
JP7266580B2 (ja) | 学童期以降の高血糖に起因する疾患の予防のための乳幼児用組成物 | |
TWI797769B (zh) | 副乾酪乳酸桿菌lm-141分離株及其用途 | |
KR102579159B1 (ko) | 신규한 사카로마이세스 보울라디 28-7 균주 및 이의 용도 | |
JP2010132580A (ja) | 脂質代謝改善効果を有する乳酸菌 |